The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effect of mevalonate pathway inhibitors on outcomes of patients (pts) with HER2-positive early breast cancer (BC) in the ALTTO trial.
 
Carmine De Angelis
Honoraria - Novartis Italy; Pfizer; Roche Italy
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; GlaxoSmithKline; Lilly; Novartis Italy
Research Funding - Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Co-inventor in the Patent application # PCT/US21/70543 (Methods for breast cancer treatment and prediction of therapeutic response)
 
Jamunarani Veeraraghavan
Patents, Royalties, Other Intellectual Property - Co-inventor in the Patent application # PCT/US21/70543 (Methods for breast cancer treatment and prediction of therapeutic response
 
Vidyalakshmi Sethunath
Employment - Foundation Medicine
Stock and Other Ownership Interests - Foundation Medicine
 
Lieveke Ameye
No Relationships to Disclose
 
Marianne Paesmans
No Relationships to Disclose
 
Sarra El-Abed
Employment - argenx (I); Astellas Pharma (I)
Research Funding - Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
 
Anup Choudhury
Employment - Novartis
 
Sylvia Napoleone
Research Funding - GlaxoSmithKline/Novartis (Inst)
 
Saranya Chumsri
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; Athenex; Athenex; bioTheranostics; bioTheranostics (Inst); Eisai; Immunomedics; Immunomedics; Immunomedics; Novartis; Novartis; Puma Biotechnology; Syndax
Research Funding - Array BioPharma; Merck
 
Martine J. Piccart-Gebhart
Consulting or Advisory Role - AstraZeneca; Camel-IDS; Frame Therapeutics; Immunomedics; Immutep; Lilly; Menarini; MSD; NBE Therapeutics; Novartis; Odonate Therapeutics; Pfizer; Roche/Genentech; Seagen; Seagen
Research Funding - AstraZeneca (Inst); Immunomedics/Gilead (Inst); Lilly (Inst); Menarini (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Radius Health (Inst); Roche/Genentech (Inst); Servier (Inst); Synthon (Inst)
Other Relationship - EU Cancer Mission Board; Oncolytics
 
Alvaro Moreno-Aspitia
Stock and Other Ownership Interests - Merrimack
Research Funding - Abbvie (Inst); Daiichi Sankyo (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Sermonix Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from the development of a xenograft model. Royalties were assigned to go to my institution and not personally
 
Henry Leonidas Gomez
Consulting or Advisory Role - AstraZeneca
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Lilly; Novartis; Roche
Research Funding - MSD Oncology
 
Giuseppe Viale
Honoraria - Daiichi Sankyo Europe GmbH; MSD Oncology; Pfizer
Consulting or Advisory Role - Bayer; Daiichi Sankyo; Dako; Menarini; MSD Oncology; Novartis; Roche/Genentech
Speakers' Bureau - Roche/Genentech
Research Funding - Cepheid (Inst); Dako/Agilent Technologies (Inst); Roche/Genentech; Ventana Medical Systems (Inst)
Travel, Accommodations, Expenses - Roche
 
Susan G. Hilsenbeck
Patents, Royalties, Other Intellectual Property - Co-inventor in the Patent application # PCT/US21/70543 (Methods for breast cancer treatment and prediction of therapeutic response)
 
Mothaffar F. Rimawi
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Genentech; Macrogenics; Novartis; Seagen
 
C. Kent Osborne
Stock and Other Ownership Interests - Genetex
Consulting or Advisory Role - AstraZeneca/Merck; Genentech/Roche; GlaxoSmithKline; Lilly; Pfizer; Puma Biotechnology; Tolmar; Ventana Medical Systems
Patents, Royalties, Other Intellectual Property - Co-inventor in the Patent application # PCT/US21/70543 (Methods for breast cancer treatment and prediction of therapeutic response); editor of Diseases of the Breast
Expert Testimony - AstraZeneca/Merck
 
Evandro de Azambuja
Honoraria - Libbs (Inst); Novartis/Pfizer (Inst); Pierre Fabre (Inst); Roche/Genentech; Seagen; Zodiac Pharma
Consulting or Advisory Role - Libbs; Novartis; Pierre Fabre; Roche/Genentech
Research Funding - AstraZeneca (Inst); GlaxoSmithKline/Novartis (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - GlaxoSmithKline; Roche/Genentech
 
Rachel Schiff
Consulting or Advisory Role - Macrogenics
Research Funding - Gilead Sciences (Inst); Puma Biotechnology
Patents, Royalties, Other Intellectual Property - Patent pending (via institution): NRF Ref. BAYM.P0312US.P1-1001123973 “A multiparameter classifier to predict response to HER2-targeted therapy without chemotherapy in HER2-positive breast cancer” No any revenue was received.; Wolters Kluwer / UpToDate